Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Blinatumomab Bridge to HSCT in Low-Burden B-ALL
NCT06111625Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Sichuan University. Primary endpoint: Progression Free Survival at 2 years. Started Sep 2023; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06111625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111625.